Document Detail

Sulindac sulfide inhibits the proliferation of colon cancer cells: diminished expression of the proliferation markers PCNA and Ki-67.
MedLine Citation:
PMID:  9149129     Owner:  NLM     Status:  MEDLINE    
We evaluated the effect of sulindac sulfide (SS), which reduces cell number and induces apoptosis in cultured colon cancer cells (CCCs), on expression of the proliferation markers PCNA and Ki-67 in HT-29 and HCT-15 CCCs; only the former express cyclooxygenases. DNA content and PCNA/Ki-67 expression were analyzed by bivariate flow cytometry. SS inhibited cell proliferation, determined by the reduced expression of PCNA and Ki-67, roughly by half at 72 h, and induced apoptosis (accounting for about two-thirds and one-third of the reduction in cell number, respectively). A similar effect of SS occurred in HT-29 and HCT-15 CCCs, and also in non-colonic cells, indicating that this rather general effect of SS on cultured cells is not dependent on inhibition of prostaglandin synthesis.
L Qiao; S J Shiff; B Rigas
Related Documents :
20026309 - Induction of apoptosis by thymoquinone in lymphoblastic leukemia jurkat cells is mediat...
18761329 - Action of resveratrol alone or in combination with roscovitine, a cdk inhibitor, on cel...
8975889 - Butyric acid-induced apoptosis of murine thymocytes, splenic t cells, and human jurkat ...
16443509 - Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovar...
15900709 - Activated cofilin colocalises with arp2/3 complex in apoptotic blebs during programmed ...
9619299 - Application of fluorescence microscopy to measure apoptosis in jurkat t cells after tre...
19188179 - Increased intratumoral foxp3-positive regulatory immune cells during interleukin-2 trea...
23581889 - Lowered nudix type 5 (nudt5) expression leads to cellular senescence in imr-90 fibrobla...
24510519 - Rise of ipscs as a cell source for adoptive immunotherapy.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer letters     Volume:  115     ISSN:  0304-3835     ISO Abbreviation:  Cancer Lett.     Publication Date:  1997 May 
Date Detail:
Created Date:  1997-06-04     Completed Date:  1997-06-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7600053     Medline TA:  Cancer Lett     Country:  IRELAND    
Other Details:
Languages:  eng     Pagination:  229-34     Citation Subset:  IM    
Department of Medicine, Cornell University Medical College, New York, NY 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / drug therapy*,  metabolism
Antineoplastic Agents / pharmacology*
Apoptosis / drug effects
Cell Count / drug effects
Cell Cycle / drug effects
Cell Division / drug effects
Colonic Neoplasms / drug therapy*,  metabolism
HL-60 Cells / drug effects,  metabolism
HT29 Cells / drug effects,  metabolism
Ki-67 Antigen / biosynthesis*,  metabolism
Proliferating Cell Nuclear Antigen / biosynthesis*,  metabolism
Sulindac / analogs & derivatives*,  pharmacology
Tumor Markers, Biological / biosynthesis*,  metabolism
Reg. No./Substance:
0/Antineoplastic Agents; 0/Ki-67 Antigen; 0/Proliferating Cell Nuclear Antigen; 0/Tumor Markers, Biological; 32004-67-4/sulindac sulfide; 38194-50-2/Sulindac

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation.
Next Document:  Marked elevation of hypusine formation activity on eukaryotic initiation factor 5A in v-HA-RAS trans...